1. Introduction {#sec1}
===============

Gastric cancer (GC) is one of the most common digestive malignancies worldwide; although its incidence has declined over the past century, it is still a major risk factor threatening human health. According to statistics, about 990,000 people are diagnosed with GC every year in the world, whose morbidity is ranked fourth in all malignant tumors \[[@B1]\]. According to the latest prediction of the American Cancer Society (ACS), there will be 27,510 new cases of GC and more than 11,000 deaths in the United States in 2019 \[[@B2]\]. Similar to other malignancies, the occurrence of GC is also a multifactor process, such as age, smoking, and *Helicobacter pylori* infection, leading to abnormal activation of oncogene and inactivation of tumor suppressor at last \[[@B3], [@B4]\]. At present, the research on the carcinogenesis of GC is still lacking. In order to innovate the clinical therapies for GC and improve the prognosis of GC patients, it is necessary to further explore the potential molecular mechanisms in the carcinogenesis and progression of GC, which may help identify possible therapeutic targets and prognostic biomarkers.

Peroxiredoxins (PRDXs) are antioxidant enzymes which can neutralise a wide range of reactive oxygen species (ROS), such as hydrogen peroxide (H~2~O~2~) and alkyl hydroperoxides. The PRDX family contains six isoforms: PRDX1, PRDX2, PRDX3, PRDX4, PRDX5, and PRDX6. As mediators in regulating ROS levels, PRDXs are localized to the cytoplasm and reduce H~2~O~2~ and alkyl hydroperoxides to water and alcohol with the use of reducing equivalents derived from thiol-containing donor molecules \[[@B5]\]. An increasing number of studies have discovered several primary mechanisms of PRDXs participating in cancerous diseases \[[@B6]--[@B8]\]. Several studies have also identified the prognostic roles of PRDXs in multiple cancers, including lung cancer \[[@B9]\], ovarian cancer \[[@B10]\], and breast cancer \[[@B11]\]. However, the exact prognostic values of PRDXs in GC have not been explored up to date.

The Kaplan--Meier (KM) plotter (<http://kmplot.com/analysis/>) is a user-friendly online website and is capable of evaluating the impacts of total 54k genes on patient\'s survival in 21 cancer types \[[@B12]\]. The primary purpose of the tool is a meta-analysis-based discovery and validation of survival biomarkers. In the current study, we applied the KM plotter database to evaluate the prognostic impacts of each PRDX mRNA expression in patients with GC. Finally, we identified PRDX1, PRDX2, PRDX3, and PRDX4 as promising prognostic candidates for monitoring GC patients and explored the potential beneficiaries by subgroup survival analysis.

2. Materials and Methods {#sec2}
========================

2.1. Survival Analysis Based on KM Plotter {#sec2.1}
------------------------------------------

In this study, we employed online KM plotter (<http://kmplot.com/analysis>) database to evaluate the prognostic values of PRDX mRNA expression for overall survival (OS) in GC patients. This database was established by collecting gene expression data and survival information from Gene Expression Omnibus (GEO), European Genome-phenome Archive (EGA), and the Cancer Genome Atlas (TCGA). The database totally contained clinical and gene expression information of 876 GC patients, and the clinical information comprised clinical stages, Lauren classifications, HER2 expression status, differentiation degree, and treatment strategies. In our study, the prognostic values of each PRDX mRNA expression in GC were assessed by the KM plotter database. In addition, we evaluated the correlations between OS of GC patients and PRDX expression according to different clinicopathological features. What needs to further explain was that the expression cutoff points of the PRDX mRNA were determined according to the median level of the gene from the selected GC specimens. GC samples were split into "low expression group" and "high expression group" depending on the comparisons between expression levels with established cutoffs.

2.2. Statistical Analysis {#sec2.2}
-------------------------

All statistical analyses were performed on the KM plotter database online. For all survival analyses, patients\' cohorts were compared with KM survival plots. Hazard ratio (HR), 95% confidence interval (95% CI), and logrank *P* value were calculated and displayed online. Differences were deemed to be statistically significant when *P* values were less than 0.05.

3. Results {#sec3}
==========

3.1. Prognostic Values of PRDX mRNA Expression in all GC Patients {#sec3.1}
-----------------------------------------------------------------

The prognostic values of PRDX1 mRNA expression were firstly evaluated in the database. OS curves were plotted for all GC patients. Low expression of PRDX1 mRNA level exhibited a notable association with worse OS in total 876 GC patients (*P* \< 0.001, HR = 0.57, 95% CI: 0.48--0.68, [Figure 1(a)](#fig1){ref-type="fig"}). The subtype analysis of different genders showed that decreased PRDX1 mRNA expression was associated with poor OS in both male (*P* \< 0.001, HR = 0.66, 95% CI: 0.53--0.82, [Figure 1(b)](#fig1){ref-type="fig"}) and female (*P*=0.02, HR = 0.66, 95% CI: 0.46--0.94, [Figure 1(c)](#fig1){ref-type="fig"}) patients.

The next evaluation for prognostic values of PRDX2 mRNA expression was performed in the database. Decreased PRDX2 mRNA expression was significantly associated with unfavourable OS in all GC patients (*P* \< 0.001, HR = 0.57, 95% CI: 0.48--0.68, [Figure 2(a)](#fig2){ref-type="fig"}), male patients (*P* \< 0.001, HR = 0.62, 95% CI: 0.50--0.76, [Figure 2(b)](#fig2){ref-type="fig"}), and female patients (*P* \< 0.001, HR = 0.52, 95% CI: 0.36--0.74, [Figure 2(c)](#fig2){ref-type="fig"}). As the results showed, female GC patients with high PRDX2 mRNA expression exhibited a 48% reduction in risk of death, which suggested prognostic evaluation using PRDX2 mRNA expression had additional value in female patients compared with male patients.

[Figure 3](#fig3){ref-type="fig"} shows the prognostic values of PRDX3 in the database. Low PRDX3 mRNA expression was significantly associated with worse OS in all GC patients (*P* \< 0.001, HR = 0.60, 95% CI: 0.50--0.71, [Figure 3(a)](#fig3){ref-type="fig"}), male patients (*P* \< 0.001, HR = 0.62, 95% CI: 0.50--0.76, [Figure 3(b)](#fig3){ref-type="fig"}), and female patients (*P*=0.002, HR = 0.57, 95% CI: 0.40--0.81, [Figure 3(c)](#fig3){ref-type="fig"}).

[Figure 4](#fig4){ref-type="fig"} illustrates prognostic impacts of PRDX4 mRNA expression in the database. Similar to the first three family members, low PRDX4 mRNA levels were remarkably correlated with poor OS in all GC patients (*P* \< 0.001, HR = 0.61, 95% CI: 0.52--0.73, [Figure 4(a)](#fig4){ref-type="fig"}), male patients (*P* \< 0.001, HR = 0.62, 95% CI: 0.50--0.77, [Figure 4(b)](#fig4){ref-type="fig"}), and female patients (*P*=0.002, HR = 0.56, 95% CI: 0.40--0.81, [Figure 4(c)](#fig4){ref-type="fig"}).

Figures [5](#fig5){ref-type="fig"} and [6](#fig6){ref-type="fig"} present prognostic association of PRDX5 and PRDX6 mRNA expression in the database, respectively. Different from the above family members, mRNA expression of both PRDX5 and PRDX6 had no obvious association with clinical outcomes. Detailed parameters are as follows: prognostic values of PRDX5 in all patients (*P*=0.077, HR = 0.82, 95% CI: 0.66--1.02, [Figure 5(a)](#fig5){ref-type="fig"}), male patients (*P*=0.375, HR = 0.88, 95% CI: 0.65--1.17, [Figure 5(b)](#fig5){ref-type="fig"}), and female patients (*P*=0.332, HR = 0.81, 95% CI: 0.53--1.24, [Figure 5(c)](#fig5){ref-type="fig"}), and prognostic values of PRDX6 in all patients (*P*=0.075, HR = 0.86, 95% CI: 0.72--1.02, [Figure 6(a)](#fig6){ref-type="fig"}), male patients (*P*=0.173, HR = 0.86, 95% CI: 0.70--1.07, [Figure 6(b)](#fig6){ref-type="fig"}), and female patients (*P*=0.305, HR = 0.83, 95% CI: 0.59--1.18, [Figure 6(c)](#fig6){ref-type="fig"}).

3.2. Subgroup Analysis of PRDXs\' Prognostic Values in GC Patients according to Clinicopathological Characteristics {#sec3.2}
-------------------------------------------------------------------------------------------------------------------

In addition to our assessments of the prognostic values of PRDX mRNA expressions in general GC patients, we further performed subtype analysis to assess the associations with different clinicopathological characteristics to identify more potential beneficiaries who may benefit from prognostic assessment using PRDX mRNA expressions, according to clinical stages, Lauren classifications, HER2 expression status, differentiation degree, and treatment strategies.

As presented in [Table 1](#tab1){ref-type="table"}, we found that low expressions of PRDX1, PRDX2, PRDX3, and PRDX4 were significantly correlated with unfavourable OS in stage III GC patients. Besides, decreased expressions of PRDX1 and PRDX4 had a notable relationship to poor OS in stage IV GC patients as well. These results suggested GC patients with advanced stages (III and IV) tend to benefit from prognostic assessment using PRDX mRNA expressions.

In [Table 2](#tab2){ref-type="table"}, we further investigated the association between PRDX expression and Lauren classifications in GC patients. The results showed that low expressions of PRDX1, PRDX2, PRDX3, and PRDX6 were remarkably correlated with poor OS in patients with intestinal GC. Besides, decreased PRDX1 and PRDX3 showed correlations with worse OS in patients with diffuse GC as well. The reason why no PRDX expressions associated with OS in mixed GC may be due to the limited number of mixed patients (only 32 patients with mixed GC).

Next, [Table 3](#tab3){ref-type="table"} reveals correlations of PRDX expressions with OS according to different HER2 status in GC patients. Both positive HER2 status and negative HER2 status were associated with poor OS in PRDX1, PRDX2, and PRDX4 mRNA expressions in GC patients. However, decreased PRDX3 only showed correlations with worse OS in patients with negative HER2 status GC. Moreover, PRDX5 and PRDX6 had no correlation with OS in both positive and negative HER2 status in GC patients.

[Table 4](#tab4){ref-type="table"} demonstrates correlations of PRDX expression with OS according to various differentiation degrees in GC patients. We found that GC patients with low expressions of PRDX2 with moderate differentiation exhibited worse OS. However, all other PRDX expressions showed no significance in OS in GC patients with different differentiation degrees. Although several positive findings were observed, we believe that the evidence provided by this subtype analysis is not strong due to the most cases in KM plotter missing the information of differentiation degrees.

Last but not least, the results in [Table 5](#tab5){ref-type="table"} exhibited the correlation of PRDX mRNA expressions with OS based on different treatment strategies in GC patients. The results revealed that expressions of PRDX2 and PRDX3 showed worse OS in GC patients treated with surgery alone. Subsequent analysis indicated that low expression of PRDX3 was also associated with poor OS in GC patients receiving 5-FU-based adjuvant chemotherapy regimens. Regretfully, all other PRDX expressions exhibited no significance in OS in GC patients receiving different treatment strategies.

4. Discussion {#sec4}
=============

PRDXs are one of the most significant antioxidant enzyme systems, which include superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPX). PRDXs tend to be remarkably overexpressed when cells are under oxidative stress conditions and mainly participate in the defense against oxidative environment \[[@B13], [@B14]\]. In the carcinogenesis of cancerous diseases, interestingly, several studies showed the double effects of PRDXs in the carcinogenesis \[[@B15]\]. Namely, overexpression of PRDXs may either inhibit cancer development or promote cancer growth, depending on the specific PRDX family member and the types of cancers.

Although recent literature studies reveal the prognostic roles of PRDXs in several cancers, the prognostic values in GC have not yet been evaluated. In the current study, we explored the prognostic roles of PRDX mRNA expression in GC patients based on the data gathered from the KM plotter. Our results revealed that decreased expression of PRDX1, PRDX2, PRDX3, and PRDX4 family members was significantly correlated with unfavourable survival in total patients suffering from GC. However, no additional value was found in PRDX5 and PRDX6 in predicting the prognosis of all GC patients.

PRDX1 is an antioxidant enzyme that can act as a promotor in inflammatory response \[[@B16]\]. Recent studies have shown that PRDX1 functioning as a potential oncogene was observed in numerous cancers, including ovarian cancer \[[@B17]\], head and neck squamous cell carcinoma \[[@B18]\], and breast cancer \[[@B19]\]. An observational research based on 189 GC cases suggested that overexpression of PRDX1 predicted poor OS in GC, and further research on mechanism revealed PRDX1 promotes GC cell invasion and metastasis through epithelial-mesenchymal transition- (EMT-) dependent mechanisms \[[@B20]\]. This seems to be inconsistent with our findings that low PRDX1 expression was associated with poor OS, but double effects of PRDXs on cancer cells have been identified previously \[[@B15]\].

PRDX2 is crucial to multiple cell processes, including cell migration, proliferation, differentiation, and carcinogenesis \[[@B21], [@B22]\]. PRDX2 is an important member of the ROS scavenging system, and deletion of PRDX2 promotes age-related ovarian failure via the ROS-mediated JNK pathway *in vivo* \[[@B23]\]. Several studies have observed the oncogene role in numerous cancers \[[@B24], [@B25]\]. However, no exact functions of PRDX2 in GC are currently established. In our research, we revealed decreased PRDX2 mRNA expression was significantly associated with unfavourable OS in GC patients, suggesting the tumor suppressor role of PRDX2 in GC.

According to previous publications, high expression PRDX3 is associated with advanced malignant phenotype and worse prognosis in hepatocellular carcinoma \[[@B26]\], endometrial cancer \[[@B27]\], and medulloblastoma \[[@B28]\]. Besides, serum proteomics-based analysis identified autoantibodies against PRDX3 as potential diagnostic biomarkers in nasopharyngeal carcinoma \[[@B29]\]. In GC, our results found that decreased PRDX3 was correlated with worse OS in all GC patients, and subgroup analysis revealed PRDX3 only was associated with poor OS in patients with negative HER2 status GC.

PRDX4 is a PRDX family member which has an exact double effect on cancer cells according to the previous publication. Guo et al. revealed that deletion of PRDX4 enhanced the risk of diethylnitrosamine- (DEN-) induced hepatocellular carcinoma in mice and low expression PRDX4 was significantly associated with poor prognosis in hepatocellular carcinoma patients. However, decreased PRDX4 repressed cell proliferation and triggered cell death pathways in hepatocellular carcinoma cell lines \[[@B15]\], suggesting the potential role of PRDX4 as activators or inhibitors in hepatocellular carcinoma with different stages and phenotypes. In GC, PRDX4 had been reported to be decreased and served as a biomarker candidate to diagnose GC \[[@B30]\]. Based on the current research, we discovered low PRDX4 mRNA expression was significantly associated with worse OS in GC patients, suggesting the tumor suppressor role of PRDX4 in GC.

PRDX5 and PRDX6 are other significant members of PRDX family. Numerous studies have revealed the potential oncogenic roles in cancers. It is believed that PRDX5 overexpression enhanced tumorigenesis and predicted poor prognosis in GC \[[@B31]\]. However, our research showed that mRNA expression of both PRDX5 and PRDX6 had no obvious association with clinical outcomes. Interestingly, low PRDX6 mRNA expression showed a significant correlation with worse OS in stage III GC patients. The reason why there were different phenomena in prognostic of PRDX5 and PRDX6 in patients with GC might be due to randomness of patients\' cohort.

5. Conclusion {#sec5}
=============

In this study, we systemically evaluated the prognostic values of six PRDX members in patients with GC using the KM plotter database. As results, we discovered that low PRDX1--4 mRNA expressions were significantly associated with deteriorated OS in GC patients, whereas PRDX5 and PRDX6 mRNA expressions had no association with OS in GC patients. In summary, our findings gave new insights into the prognostic values of PRDX mRNA and provided primary evidences that PRDXs are involved in the mechanism of carcinogenesis of GC.
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![The prognostic value of PRDX4 expression in KM plotter. The valid Affymetrix ID is 201923_at (PRDX4). Survival curves are plotted for (a) all patients (*n* = 876), HR = 0.61 (95% CI: 0.52--0.73); (b) male patients (*n* = 545), HR = 0.62 (95% CI: 0.50--0.77); and (c) female patients (*n* = 236), HR = 0.56 (95% CI: 0.40--0.81).](BMRI2020-3948183.004){#fig4}

![The prognostic value of PRDX5 expression in KM plotter. The valid Affymetrix ID is 1560587_s\_at (PRDX5). Survival curves are plotted for (a) all patients (*n* = 631), HR = 0.82 (95% CI: 0.66--1.02); (b) male patients (*n* = 349), HR = 0.88 (95% CI: 0.65--1.17); and (c) female patients (*n* = 187), HR = 0.81 (95% CI: 0.53--1.24).](BMRI2020-3948183.005){#fig5}

![The prognostic value of PRDX6 expression in KM plotter. The valid Affymetrix ID is 200845_s\_at (PRDX6). Survival curves are plotted for (a) all patients (*n* = 876), HR = 0.86 (95% CI: 0.72--1.02); (b) male patients (*n* = 545), HR = 0.86 (95% CI: 0.70--1.07); and (c) female patients (*n* = 236), HR = 0.83 (95% CI: 0.59--1.18).](BMRI2020-3948183.006){#fig6}

###### 

Association between PRDX expression and OS in GC patients at different clinical stages.

  PRDXs   Clinical stages   Cases   Low   High                HR (95% CI)         *P* value
  ------- ----------------- ------- ----- ------------------- ------------------- -----------
  PRDX1   I                 67      34    33                  0.51 (0.17--1.52)   0.217
  II      140               70      70    0.80 (0.43--1.46)   0.462               
  III     315               152     153   0.53 (0.40--0.71)   \<0.001             
  IV      148               74      74    0.57 (0.39--0.84)   0.004               
                                                                                  
  PRDX2   I                 67      34    33                  1.15 (0.43--3.08)   0.787
  II      140               70      70    0.79 (0.43--1.44)   0.439               
  III     315               152     153   0.53 (0.40--0.71)   \<0.001             
  IV      148               74      74    0.79 (0.54--1.15)   0.219               
                                                                                  
  PRDX3   I                 67      34    33                  0.51 (0.17--1.52)   0.218
  II      140               70      70    0.79 (0.43--1.44)   0.749               
  III     315               152     153   0.62 (0.46--0.82)   \<0.001             
  IV      148               74      74    0.86 (0.58--1.25)   0.425               
                                                                                  
  PRDX4   I                 67      34    33                  0.75 (0.28--2.03)   0.571
  II      140               70      70    0.94 (0.51--1.72)   0.836               
  III     315               152     153   0.67 (0.50--0.89)   0.005               
  IV      148               74      74    0.66 (0.45--0.96)   0.031               
                                                                                  
  PRDX5   I                 62      31    31                  0.93 (0.31--2.78)   0.897
  II      135               68      67    1.41 (0.74--2.68)   0.294               
  III     197               98      99    1.03 (0.71--1.50)   0.866               
  IV      140               70      70    0.92 (0.62--1.36)   0.660               
                                                                                  
  PRDX6   I                 67      34    33                  0.63 (0.23--1.74)   0.367
  II      140               70      70    0.92 (0.51--1.67)   0.787               
  III     315               152     153   0.72 (0.54--0.96)   0.025               
  IV      148               74      74    0.90 (0.62--1.32)   0.607               

###### 

Association between PRDX expression and OS in GC patients with different Lauren classifications.

  PRDXs     Lauren classification   Cases   Low   High                HR (95% CI)         *P* value
  --------- ----------------------- ------- ----- ------------------- ------------------- -----------
  PRDX1     Intestinal              320     160   160                 0.56 (0.41--0.78)   \<0.001
  Diffuse   241                     120     121   0.59 (0.42--0.84)   0.003               
  Mixed     32                      16      16    0.75 (0.27--2.06)   0.571               
                                                                                          
  PRDX2     Intestinal              320     160   160                 0.47 (0.34--0.65)   \<0.001
  Diffuse   241                     120     121   0.99 (0.70--1.39)   0.949               
  Mixed     32                      16      16    1.24 (0.44--3.52)   0.680               
                                                                                          
  PRDX3     Intestinal              320     160   160                 0.59 (0.43--0.81)   \<0.001
  Diffuse   241                     120     121   0.66 (0.47--0.93)   0.017               
  Mixed     32                      16      16    0.53 (0.19--1.50)   0.222               
                                                                                          
  PRDX4     Intestinal              320     160   160                 0.76 (0.55--1.04)   0.088
  Diffuse   241                     120     121   0.72 (0.51--1.01)   0.054               
  Mixed     32                      16      16    0.51 (0.18--1.44)   0.197               
                                                                                          
  PRDX5     Intestinal              269     134   135                 0.92 (0.64--1.32)   0.640
  Diffuse   240                     120     120   0.85 (0.61--1.20)   0.360               
  Mixed     29                      14      15    1.22 (0.41--3.65)   0.721               
                                                                                          
  PRDX6     Intestinal              320     160   160                 0.67 (0.49--0.92)   0.012
  Diffuse   241                     120     121   0.86 (0.61--1.21)   0.384               
  Mixed     32                      16      16    1.51 (0.54--4.26)   0.429               

###### 

Association between PRDX expression and OS in GC patients with different HER2 expression status.

  PRDXs      HER2 status   Cases   Low   High                HR (95% CI)         *P* value
  ---------- ------------- ------- ----- ------------------- ------------------- -----------
  PRDX1      Negative      532     266   266                 0.62 (0.49--0.77)   \<0.001
  Positive   344           172     172   0.75 (0.58--0.98)   0.031               
                                                                                 
  PRDX2      Negative      532     266   266                 0.66 (0.52--0.82)   \<0.001
  Positive   344           172     172   0.56 (0.43--0.73)   \<0.001             
                                                                                 
  PRDX3      Negative      532     266   266                 0.51 (0.40--0.64)   \<0.001
  Positive   344           172     172   0.97 (0.75--1.25)   0.809               
                                                                                 
  PRDX4      Negative      532     266   266                 0.63 (0.51--0.79)   \<0.001
  Positive   344           172     172   0.72 (0.56--0.94)   0.014               
                                                                                 
  PRDX5      Negative      429     214   215                 0.89 (0.68--1.16)   0.390
  Positive   202           101     101   0.77 (0.53--1.12)   0.171               
                                                                                 
  PRDX6      Negative      532     266   266                 0.81 (0.65--1.01)   0.061
  Positive   344           172     172   1.05 (0.81--1.35)   0.737               

###### 

Association between PRDX expression and OS in GC patients with different differentiation degree.

  PRDXs      Differentiation degree   Cases   Low   High                HR (95% CI)         *P* value
  ---------- ------------------------ ------- ----- ------------------- ------------------- -----------
  PRDX1      Poor                     165     82    83                  1.40 (0.94--2.08)   0.098
  Moderate   67                       34      33    0.85 (0.44--1.63)   0.629               
  Good       32                       16      16    1.07 (0.46--2.54)   0.870               
                                                                                            
  PRDX2      Poor                     165     82    83                  0.87 (0.58--1.30)   0.494
  Moderate   67                       34      33    0.32 (0.16--0.63)   \<0.001             
  Good       32                       16      16    0.61 (0.26--1.46)   0.268               
                                                                                            
  PRDX3      Poor                     165     82    83                  1.06 (0.71--1.57)   0.792
  Moderate   67                       34      33    0.57 (0.30--1.10)   0.091               
  Good       32                       16      16    0.66 (0.28--1.57)   0.344               
                                                                                            
  PRDX4      Poor                     165     82    83                  1.25 (0.84--1.86)   0.271
  Moderate   67                       34      33    0.59 (0.30--1.14)   0.113               
  Good       32                       16      16    0.48 (0.20--1.17)   0.099               
                                                                                            
  PRDX5      Poor                     121     60    61                  1.15 (0.71--1.86)   0.573
  Moderate   67                       34      33    0.82 (0.43--1.57)   0.544               
  Good       5                        2       3     ---                 0.221               
                                                                                            
  PRDX6      Poor                     165     82    83                  0.88 (0.59--1.30)   0.512
  Moderate   67                       34      33    1.10 (0.57--2.11)   0.775               
  Good       32                       16      16    1.33 (0.56--3.13)   0.518               

###### 

Association between PRDX expression and OS in GC patients with different treatment strategies.

  PRDXs                 Treatment strategies   Cases   Low   High                HR (95% CI)         *P* value
  --------------------- ---------------------- ------- ----- ------------------- ------------------- -----------
  PRDX1                 Surgery alone          380     190   190                 0.76 (0.57--1.01)   0.057
  5-FU-based adjuvant   153                    76      77    1.21 (0.86--1.71)   0.268               
  Other adjuvants       76                     38      38    0.67 (0.27--1.64)   0.374               
                                                                                                     
  PRDX2                 Surgery alone          380     190   190                 0.72 (0.54--0.96)   0.025
  5-FU-based adjuvant   153                    76      77    0.68 (0.48--0.97)   0.030               
  Other adjuvants       76                     38      38    0.61 (0.25--1.50)   0.276               
                                                                                                     
  PRDX3                 Surgery alone          380     190   190                 0.74 (0.55--0.99)   0.038
  5-FU-based adjuvant   153                    76      77    1.20 (0.85--1.69)   0.296               
  Other adjuvants       76                     38      38    0.94 (0.39--2.26)   0.883               
                                                                                                     
  PRDX4                 Surgery alone          380     190   190                 0.85 (0.64--1.14)   0.275
  5-FU-based adjuvant   153                    76      77    0.78 (0.56--1.11)   0.164               
  Other adjuvants       76                     38      38    1.01 (0.42--2.43)   0.990               
                                                                                                     
  PRDX5                 Surgery alone          380     191   189                 0.82 (0.62--1.10)   0.187
  5-FU-based adjuvant   34                     17      17    0.94 (0.38--2.33)   0.893               
  Other adjuvants       76                     38      38    0.48 (0.19--1.20)   0.110               
                                                                                                     
  PRDX6                 Surgery alone          380     190   190                 1.04 (0.78--1.38)   0.795
  5-FU-based adjuvant   153                    76      77    0.98 (0.70--1.38)   0.913               
  Other adjuvants       76                     38      38    1.16 (0.48--2.80)   0.738               

[^1]: Academic Editor: Toshimi Chiba
